Global health

Worldwide Anti-Smoking Policies Charted in Comprehensive Index

Retrieved on: 
Wednesday, April 3, 2024
Other Policy Issues, Women, Men, Other Retail, General Health, Tobacco, Public Safety, Public Policy, Government, Other Health, Consumer, Advocacy Group Opinion, Retail, Oncology, Other Communications, Communications, Convenience Store, Philanthropy, Health, White House, Federal Government, Foundation, Herbal cigarette, Innovation, Global health, History, Smoking, European, THP, Nicotine, Multimedia

We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index ( https://antismoking.global/ ).

Key Points: 
  • We Are Innovation, a leading global innovation network, released the 2024 Effective Anti-Smoking Policies Global Index ( https://antismoking.global/ ).
  • The Index delves into the intricacies of alternative nicotine products, scrutinizing aspects such as regulatory frameworks, prohibitions, taxation, and governmental measures for switching from smoking.
  • View the full release here: https://www.businesswire.com/news/home/20240402477735/en/
    The top 20 countries in the global anti-smoking index, led by the United Kingdom, Sweden, and Slovakia in the podium positions, collectively impact almost 1 billion people worldwide.
  • The index emphasizes the urgent need for global advancements in anti-smoking policies.

PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1

Retrieved on: 
Monday, April 1, 2024
Oncology, Health, Medical Devices, Infectious Diseases, Health Technology, Pharmaceutical, Biotechnology, MSD, Research, Clinical research, Government, Congress, Global health, Policy, Cancer, University, Infection, Former, Injection, Emerita, SAB, Immune system, Therapy, Use, Multimedia, Vaccine, Chiron, Medical director

The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.

Key Points: 
  • The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.
  • View the full release here: https://www.businesswire.com/news/home/20240401778401/en/
    In the countries highlighted, PharmaJet has commercial and development partners for prophylactic vaccines for the prevention of infectious diseases as well as cancer treatments.
  • To date, more than 10 million vaccinations have been made and PharmaJet has over 80 global development partners.
  • To find out how this innovative technology can help your vaccine or therapeutic program, schedule a meeting with one of our company experts by clicking here .

Global Disposable Gloves Market Outlook & Forecast 2024-2029, Featuring Key Vendors Ansell, Hartalega Holdings, Kossan Rubber Industries, Rubberex, Supermax, Top Glove and UG Healthcare - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Manufacturing, Other Manufacturing, Health, Chemicals, Plastics, Medical Supplies, Hospital, Research, Sanitation, Oil, Dentistry, Growth, Prevalence, Face, Agriculture, Mechanics, Beauty, COVID-19, Global health, Patient, Kossan Rubber Industries, Electronics, Health care, Latex, Laboratory, Surgeon, Infection, LaTeX, Water, Traction, Hygiene, Safety, B2B, Cosmetics, Neoprene, USD, Dentist, Medical device

The global disposable gloves market is characterized by dynamic and competitive forces shaped by supply and demand factors.

Key Points: 
  • The global disposable gloves market is characterized by dynamic and competitive forces shaped by supply and demand factors.
  • Prominent manufacturers include Ansell, Hartalega Holdings, Kossan Rubber Industries, Rubberex, Supermax, Top Glove, and UG Healthcare.
  • The global disposable gloves market, mainly fueled by the rising demand for nitrile gloves, stands at a pivotal juncture.
  • Disposable gloves have become indispensable in healthcare, food processing, manufacturing, and other sectors, shaping a robust market landscape in the region.

Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

Retrieved on: 
Monday, April 1, 2024
Health, Stem Cells, Genetics, General Health, Research, Science, Biotechnology, Stem cell, B cell, Regenerative medicine, Agriculture, Global health, Lineage, Madrona Venture Group, Duke University, Beckman Research Institute, City, Columbia University, University, NanoString Technologies, Fierce, Doctor of Philosophy, Investment, Therapy, Microbiology, Partner, Corporate development, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
  • Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
  • “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
  • Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.

Herbalife Announces Proposed Offering of $700 Million Aggregate Principal Amount of Senior Secured Notes

Retrieved on: 
Monday, April 1, 2024
Retail, Health, Other Retail, Fitness & Nutrition, Specialty, Vitamins, Supplements, Debt-to-GDP ratio, Global health, HLF, Regulation, Sale, Security (finance)

Herbalife Ltd. (NYSE: HLF) (the “Company”), a global health and wellness company, today announced that HLF Financing SaRL, LLC and Herbalife International, Inc., each a wholly owned subsidiary of the Company, intend, subject to market and other conditions, to offer $700 million aggregate principal amount of senior secured notes due 2029 (the “Notes”).

Key Points: 
  • Herbalife Ltd. (NYSE: HLF) (the “Company”), a global health and wellness company, today announced that HLF Financing SaRL, LLC and Herbalife International, Inc., each a wholly owned subsidiary of the Company, intend, subject to market and other conditions, to offer $700 million aggregate principal amount of senior secured notes due 2029 (the “Notes”).
  • The Company expects to use the net proceeds from the offering to repay indebtedness, including borrowings outstanding under the Company’s senior secured credit facility and a portion of the Company’s 7.875% Senior Notes due 2025, to pay related fees and expenses and the remainder for general corporate purposes.
  • Any offer, if at all, will be made only pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States in reliance on Regulation S under the Securities Act.
  • The Notes have not been and are not expected to be registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Global Clinical Trials Connect Conference 2024: London, United Kingdom - May 28-29, 2024 - Registration Now Open - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Health, Health Technology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, ChromeOS, External, Learning, Partnership, Global health, Bioethics, Pleasure, Pharma

The "Global Clinical Trials Connect 2024" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trials Connect 2024" conference has been added to ResearchAndMarkets.com's offering.
  • The Global Clinical Trials Connect 2024 will provide a platform to discuss on the futuristic advancements in clinical trials and clinical research.
  • This multidisciplinary program involves broad participation of people from clinical trials community from around the globe who are focused on learning more about clinical research, clinical trials planning and management.
  • It gives us a great pleasure in welcoming you to the Global Clinical Trials Connect 2024.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
Friday, March 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Tuesday, March 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Care Access Opens New Clinical Research Site in Warsaw, Poland

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Community, Global health, Patient, Acquisition, Senior, Access, Multimedia, Physician, Medicine

Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland.

Key Points: 
  • Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland.
  • The company’s expansion in Poland reinforces its commitment to improving access to clinical research globally through its innovative model of bringing clinical trials wherever they are needed.
  • (Photo: Business Wire)
    In recent years, Care Access has been active in clinical research across Europe, and now, by establishing a new facility in Warsaw, Care Access is further expanding its European services aimed to implement its industry-leading research capabilities, such as its Community Screening Program, Sites On Demand, and Mobile Research Site Infrastructure.
  • “The Warsaw site will improve access to advanced health screenings and research opportunities to communities throughout Poland.”
    Collaboration with local physicians is a key approach to how Care Access improves access to clinical research in more communities.

Decolonizing Global Health a Must, says Pandemic Panel

Retrieved on: 
Tuesday, March 12, 2024
Public Policy, Government, AIDS, Health, COVID-19, Healthcare Reform, Infectious Diseases, Advocacy Group Opinion, AIDS Healthcare Foundation, Public health, University, Executive, Global health, Public, School of Public Health, WHO, AHF, Pandemic, School, Pharmaceutical industry

On March 8, during the CUGH 2024 conference , the AHF Global Public Health Institute and the University of California, Berkeley, School of Public Health convened a panel titled "Decolonizing Global Health Financing: Charting an Equitable Path Forward."

Key Points: 
  • On March 8, during the CUGH 2024 conference , the AHF Global Public Health Institute and the University of California, Berkeley, School of Public Health convened a panel titled "Decolonizing Global Health Financing: Charting an Equitable Path Forward."
  • This focused session shed light on redefining global health funding mechanisms to support pandemic prevention, preparedness, and response and reconstructing global health financing through equitable and sustainable partnerships.
  • Decolonizing global health is critical to addressing global health emergencies.
  • Regions should have the power to declare their own public health emergencies to mobilize international resources to respond to them effectively.”
    As countries negotiate to reshape the existing global health security architecture , it is vital that they adequately address decolonizing global health financing as a critical imperative.